Physician

Frederick Lee Flynt, M.D.

According to 2025 Medicare claims, Frederick Flynt, M.D. (NPI: 1235356247) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Newton, GA. This provider's primary affiliated billing organization is UNIVERSITY CANCER & BLOOD CENTER LLC (NPI: 1346343761; TIN: 20-1842623) and primary practice location at 30607-1465.

Flynt's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 730 traditional Medicare patients, billed 120,250 HCPCS/CPT codes, and received $2,380,715 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,799 prescription claims across 356 beneficiaries totaling $4,411,492 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 76 claims. Open Payments data shows 89 records totaling $36,041. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $27,306 to $4,411,492. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $487 to $131,495.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	556	62,746	$719,416
2017	701	214,552	$1,992,263
2018	745	285,906	$2,558,713
2019	777	241,060	$2,903,825
2020	709	215,416	$3,062,494
2021	977	309,851	$4,767,733
2022	847	265,146	$4,606,088
2023	753	187,295	$3,286,733
2024	730	120,250	$2,380,715

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	11	14	$27,306
2016	110	403	$279,324
2017	210	1,378	$1,210,298
2018	243	1,388	$2,128,548
2019	266	1,639	$2,270,869
2020	274	1,671	$2,935,971
2021	344	2,100	$2,830,180
2022	343	1,975	$2,705,482
2023	335	1,933	$4,195,997
2024	356	1,799	$4,411,492

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	81	$10,784
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	22	134	$8,983
2021	N/R	70	$4,863
2022	N/R	65	$2,235
2023	N/R	52	$1,304
2024	N/R	76	$2,921

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	539	1,467	$90
36415	Insertion of needle into vein for collection of blood sample	442	1,198	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	435	1,205	$8
83615	Lactate dehydrogenase (enzyme) level	250	413	$6
84550	Uric acid level, blood	251	414	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	26	780	$453,981
Pomalyst	Pomalidomide	17	476	$380,918
Neulasta Onpro	Pegfilgrastim	46	826	$332,164
Revlimid	Lenalidomide	19	523	$329,193
Sandostatin Lar Depot	Octreotide Acetate,mi-Spheres	33	1,036	$251,779

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	28	$1,298
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest	Y	N/R	28	$1,219
K0001	Standard wheelchair	Y	N/R	20	$403

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	87	$1,918	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$34,122	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Frederick Lee Flynt, M.D.?

Tedicare shows public-source Medicare data for Frederick Lee Flynt, M.D. (NPI 1235356247), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Frederick Lee Flynt, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Frederick Lee Flynt, M.D.?

Frederick Lee Flynt, M.D. is linked to UNIVERSITY CANCER & BLOOD CENTER LLC (billing NPI 1346343761) in the available physician profile data.

Does Frederick Lee Flynt, M.D. have Open Payments data?

Frederick Lee Flynt, M.D. has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.